

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

ZJ

中基長壽科學

ZHONG JI LONGEVITY SCIENCE

Zhong Ji Longevity Science Group Limited

中基長壽科學集團有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 767)

**APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR,
APPOINTMENT OF MEMBER OF BOARD COMMITTEE
AND
ESTABLISHMENT OF RISK MANAGEMENT COMMITTEE**

The Board announce that with effect from 31 March 2022:

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

Mr. Lee See Barry has been appointed as an independent non-executive Director of the Company and a member of each of the Audit Committee, Remuneration Committee, Nomination Committee and Share Award Committee of the Board.

ESTABLISHMENT OF RISK MANAGEMENT COMMITTEE

In order to improve the risk management of the Company, the Board has established the Risk Management Committee in accordance with the Bye-laws of the Company.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND MEMBER OF BOARD COMMITTEE

The board (the “**Board**”) of directors (the “**Director(s)**”) of Zhong Ji Longevity Science Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Mr. Lee See Barry (“**Mr. Lee**”) has been appointed as an independent non-executive Director and a member of each of the Audit Committee, Remuneration Committee, Nomination Committee and Share Award Committee of the Board with effect from 31 March 2022.

The biographical details of Mr. Lee are set out as follows:

Mr. Lee, aged 56, graduated from Lingnan University, Hong Kong, in 1990 with a diploma (honours) in the financial service profession. Currently, he is a fellow member of the Association of Chartered Certified Accountants. Mr. Lee has over 30 years of experience in audit, accounting and financial management. He has served as a senior partner of Sysble Consultants* (思博顧問) since 2005, during which, it serves as the financial controller of its major customers, China CBM Group and Oriental Speech Therapy* (東方啟音言語治療).

As at the date of this announcement, Mr. Lee has confirmed that save as disclosed above, he (i) does not have any relationship with any Director, senior management, or substantial or controlling shareholder (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) (the “Listing Rules”)) of the Company; (ii) does not have, and is not deemed to have, any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (iii) does not hold any other directorship in the last three years in public companies, the securities of which are listed on any securities market in Hong Kong or overseas; and (iv) does not hold any other positions in the Group.

Mr. Lee has entered into an appointment letter with the Company with an initial term of two years. Mr. Lee is subject to retirement by rotation and re-election, if applicable, at the annual general meeting at least once every three years in accordance with the bye-laws of the Company and the Corporate Governance Code set out in Appendix 14 to the Listing Rules. He is entitled to receive a director’s fee of HK\$20,000 per month, which is determined by both the remuneration committee of the Company and the Board, subject to annual review with reference to the prevailing market conditions, his duties and responsibilities and time spent on the affairs of the Company.

Save as disclosed above, there is no other information in relation to the appointment of Mr. Lee to be disclosed pursuant to any of the requirements of Rule 13.51(2) of the Listing Rules, and there is no other matter that needs to be brought to the attention of the shareholders of the Company.

The Board would like to extend its welcome to Mr. Lee for his new position in the Company.

ESTABLISHMENT OF RISK MANAGEMENT COMMITTEE

In order to improve the risk management of the Company, the Board has established the Risk Management Committee in accordance with the Bye-laws of the Company with effect from 31 March 2022.

The members of the Risk Management Committee are Mr. Tam Ho Leung Simon, Ms. Wang Weixia, Mr. Chai Nan and Mr. Lee See Barry has been appointed as the chairman of the Risk Management Committee. The terms of reference of the Risk Management Committee will be published on the website of the Company.

By order of the Board
Zhong Ji Longevity Science Group Limited
Yan Li
Chairman

Hong Kong, 31 March 2022

As at the date of this announcement, the Directors are:

Executive Directors

Mr. Yan Li (*Chairman*)
Mr. Li Jiuhua (*Chief Executive Officer*)
Mr. Li Xiaoshuang
Ms. Cao Xie Qiong

Independent non-executive Directors

Mr. Tam Ho Leung Simon
Ms. Wang Weixia
Mr. Chai Nan
Mr. Lee See Barry

Non-executive Directors

Dr. He Yiwu
Ms. Choi Ngai Wah

In the case of any inconsistency, the English text of this announcement shall prevail over the Chinese text.

* *For identification purpose only*